Prosight Management as of March 31, 2024
Portfolio Holdings for Prosight Management
Prosight Management holds 44 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Shattuck Labs (STTK) | 9.3 | $33M | 3.7M | 8.94 | |
| Adc Therapeutics Sa SHS (ADCT) | 8.8 | $32M | 7.1M | 4.49 | |
| Galapagos Nv Spon Adr (GLPG) | 8.3 | $30M | 932k | 32.20 | |
| Meiragtx Holdings (MGTX) | 6.8 | $24M | 4.0M | 6.07 | |
| Kura Oncology (KURA) | 5.7 | $21M | 960k | 21.33 | |
| Roivant Sciences SHS (ROIV) | 5.5 | $20M | 1.9M | 10.54 | |
| Bridgebio Pharma (BBIO) | 5.1 | $18M | 590k | 30.92 | |
| Cytokinetics Com New (CYTK) | 4.8 | $17M | 245k | 70.11 | |
| Medtronic SHS (MDT) | 4.4 | $16M | 180k | 87.15 | |
| Orthopediatrics Corp. (KIDS) | 3.4 | $12M | 418k | 29.16 | |
| Mirum Pharmaceuticals (MIRM) | 3.2 | $12M | 465k | 25.12 | |
| Guardant Health (GH) | 2.7 | $9.7M | 470k | 20.63 | |
| Kelly Svcs Cl A (KELYA) | 2.4 | $8.7M | 349k | 25.04 | |
| Abcellera Biologics (ABCL) | 2.3 | $8.1M | 1.8M | 4.53 | |
| Erasca (ERAS) | 2.1 | $7.5M | 3.7M | 2.06 | |
| BioCryst Pharmaceuticals (BCRX) | 2.0 | $7.1M | 1.4M | 5.08 | |
| Immunovant (IMVT) | 1.8 | $6.3M | 195k | 32.31 | |
| Pfizer (PFE) | 1.7 | $6.0M | 215k | 27.75 | |
| Alkermes SHS (ALKS) | 1.6 | $5.8M | 215k | 27.07 | |
| Universal Hlth Svcs CL B (UHS) | 1.5 | $5.5M | 30k | 182.46 | |
| Maravai Lifesciences Hldgs I Com Cl A (MRVI) | 1.4 | $5.2M | 600k | 8.67 | |
| Zymeworks Del (ZYME) | 1.2 | $4.3M | 411k | 10.52 | |
| Prothena Corp SHS (PRTA) | 1.2 | $4.2M | 171k | 24.77 | |
| Neurocrine Biosciences (NBIX) | 1.2 | $4.2M | 31k | 137.92 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $3.9M | 101k | 39.24 | |
| Relay Therapeutics (RLAY) | 1.0 | $3.7M | 450k | 8.30 | |
| Cogent Biosciences (COGT) | 1.0 | $3.7M | 556k | 6.72 | |
| Option Care Health Com New (OPCH) | 0.9 | $3.4M | 100k | 33.54 | |
| Viking Therapeutics (VKTX) | 0.9 | $3.2M | 39k | 82.00 | |
| Dex (DXCM) | 0.9 | $3.2M | 23k | 138.70 | |
| Barrett Business Services (BBSI) | 0.8 | $3.0M | 24k | 126.72 | |
| Ovid Therapeutics (OVID) | 0.8 | $3.0M | 983k | 3.05 | |
| Pacira Pharmaceuticals (PCRX) | 0.8 | $2.8M | 94k | 29.22 | |
| Zimmer Holdings (ZBH) | 0.7 | $2.5M | 19k | 131.98 | |
| Mural Oncology Pub Ord Shs (MURA) | 0.5 | $2.0M | 400k | 4.89 | |
| Lenz Therapeutics | 0.4 | $1.5M | 65k | 22.33 | |
| 10x Genomics Cl A Com (TXG) | 0.3 | $1.1M | 30k | 37.53 | |
| Biomea Fusion (BMEA) | 0.3 | $1.1M | 75k | 14.95 | |
| Nuvation Bio Com Cl A (NUVB) | 0.3 | $910k | 250k | 3.64 | |
| Privia Health Group (PRVA) | 0.2 | $882k | 45k | 19.59 | |
| Kezar Life Sciences (KZR) | 0.2 | $869k | 964k | 0.90 | |
| Agios Pharmaceuticals (AGIO) | 0.2 | $731k | 25k | 29.24 | |
| Avrobio Ord (AVRO) | 0.2 | $725k | 567k | 1.28 | |
| Absci Corp (ABSI) | 0.0 | $142k | 25k | 5.68 |
